Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 28 of 58, showing 10 Applications out of 576 total, starting on record 271, ending on 280

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

271.

ECCT/21/06/10   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Kishorchandra Narsinh Mandaliya
Site(s) in Kenya
1. Kenya Medical Research Institute (Kisumu county)
2. KEMRI/Walter Reed Project Research Center (Kericho county)
3. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county)
4. KEMRI CMR (Kisumu county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Kakamega county)
10. Ganjoni Clinic (Mombasa county)
 
16-08-2021 View

272.

ECCT/21/11/01   VAT 00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Walter Godfrey Jaoko
Site(s) in Kenya
1. Kenya Medical Research Institute (Kisumu county)
2. KEMRI/Walter Reed Project Research Center (Kericho county)
3. KEMRI/CCR Partners in Health R&D (PHRD) (Kiambu county)
4. KEMRI CMR (Kisumu county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Kakamega county)
10. Ganjoni Clinic (Mombasa county)
 
15-01-2022 View

273.

ECCT/21/06/07   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Samuel Ouma Gurrion Ouma
Site(s) in Kenya
1. Kenya Medical Research Institute Kisumu Clinical Research Site (Kisumu county)
2. KEMRI/Walter Reed Project Research Center (Kericho county)
3. Ganjoni Clinic (Mombasa county)
4. KEMRI/CCR Partners in Health R&D (PHRD (Nairobi City county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Kakamega county)
 
16-08-2021 View

274.

ECCT/21/06/02   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older.   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. Kenya Medical Research Institute (Nairobi City county)
2. KEMRI/Walter Reed Project Research Center-Kericho (Kericho county)
3. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center-Kisumu (Kisumu county)
4. Ganjoni Clinic – Mombasa (Mombasa county)
5. KEMRI/CCR Partners in Health R&D (PHRD)-Thika (Kiambu county)
6. Kenya Medical Research Institute (Kisumu county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital-Nairobi (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site- Butere (Kakamega county)
 
02-08-2021 View

275.

ECCT/21/03/03   PrEP My Way
    A Novel PrEP Delivery System to Meet the Needs of Young African Women   
Principal Investigator(s)
1. Prof. Elizabet Ann Bukusi
Site(s) in Kenya
Kisumu
 
06-07-2021 View

276.

ECCT/15/10/02  
    A non-randomized, open label, single dose, pharmacokinetics, safety and tolerability study of Captopril 50mgs in healthy Kenyan Adults.   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
KEMRI centre for clinical Research
 
02-12-2015 View

277.

ECCT/24/10/03   EDE Scanner Study
    A non-interventional clinical validation study of the Exponential Deep Examination (EDE) scanner in the detection of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria   
Principal Investigator(s)
1. VIDELIS Nduba
2. Berngards Ogutu
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI/CRDR Siaya Clinical trials Annex (Siaya county)
3. VICTORIA BIOMEDICAL RESEARCH INSTITUTE (Kisumu county)
 
07-04-2025 View

278.

ECCT/25/05/12   SAFIRE
    A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR)
 
15-10-2025 View

279.

ECCT/20/12/03   CALINA STUDY
    A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.   Study number: CCOA566B2307   
Principal Investigator(s)
1. Benhards Ragama Ogutu
Site(s) in Kenya
KEMRI-Centre for Clinical Research (CCR)
 
08-03-2021 View

280.

ECCT/22/03/04   VIBRI COVID-19-001/2021
    A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).   
Principal Investigator(s)
1. Dr. Lucas Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute,
 
04-05-2022 View